SYDNEY — The increased risk of cancer in people with diabetes is higher for women than men, according to a major study by Australian researchers.
Women with diabetes were also at greater risk than men of getting leukemia and stomach, mouth and kidney cancers, the George Institute for Global Health medical research group said in a statement on Friday.
Previous research identified the link between diabetes and cancer risk, but this study looked at whether that risk differs between men and women.
Among people with diabetes, women have a 6 percent higher risk of cancer than men, the researchers said in the study, published in the journal Diabetologia.
For women with type 1 or type 2 diabetes, the cancer risk is 27 percent higher compared to other women. And men with diabetes have a 19 percent higher cancer risk than men who don’t have the blood sugar disease, the findings showed.
And, for men the risk was 19 percent higher. The numbers “highlight the need for more research into the role diabetes plays in developing cancer” and “demonstrate the increasing importance of sex specific research,” said the researchers.
And based on the researchers’ analysis of data from 47 studies, diabetics of both sexes are at greater risk of cancer than people without diabetes.
“Further studies are needed to clarify the mechanisms underlying the sex differences in the diabetes-cancer association,” the study authors concluded.
Cancer is the second leading cause of death worldwide, accounting for 8.7 million deaths in 2015. About one in four women and one in three men will develop cancer during their lifetime, the study authors noted in a journal news release.
Similary, diabetes affects more than 415 million people worldwide, with 5 million deaths linked to it every year.
With Inputs from AgencyFollow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost